[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling
[培美曲塞 + 索拉非尼] 抑制 ERBB1/2/3-PI3K-NFκB 补偿性生存信号可增加致死率
期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.8281
Laurence Booth, Jane L Roberts, Mehrad Tavallai, John Chuckalovcak, Daniel K Stringer, Antonis E Koromilas, David L Boone, William P McGuire, Andrew Poklepovic, Paul Dent
